AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12860257 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36
Study 12860257 — intervention group
Group type: EXPERIMENTAL
Intervention: CETi‐1 vaccine
Number of subjects: 36
Study 11432180 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater palatine nerve block
Number of subjects: 10
Study 11432180 — intervention group
Group type: COMPARATOR
Intervention: Palatal infiltration with 2% plain lidocaine
Number of subjects: 10
Study 11432180 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal infiltration with 2% lidocaine plus 1:80,000 epinephrine
Number of subjects: 10
Study 9350242 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + HCFU (intravenous MMC 6 mg/m2 on the day of operation followed by oral HCFU for 12 months from 2 weeks after operation)
Number of subjects: 1606
Study 9350242 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + HCFU
Number of subjects: 1606
Study 9350242 — intervention group
Group type: COMPARATOR
Intervention: Operation only (Group Y)
Number of subjects: 1606
Study 8478958 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of ethanol (approximately two average drinks) per day for three menstrual cycles
Number of subjects: 34
Study 3533551 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration of controlled release theophylline (Uniphyllin)
Number of subjects: 17
Study 3533551 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of controlled release theophylline (Uniphyllin)
Number of subjects: 17
Study 3533551 — intervention group
Group type: COMPARATOR
Intervention: Control (morning vs evening administration)
Number of subjects: 17
Study 31829943 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent optimisation group
Number of subjects: 1396
Study 31829943 — intervention group
Group type: COMPARATOR
Intervention: Non-optimisation group
Number of subjects: 1396
Study 31482309 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE + taurine
Number of subjects: 12
Study 31482309 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MAOT + taurine
Number of subjects: 12
Study 31482309 — intervention group
Group type: COMPARATOR
Intervention: TTE + placebo
Number of subjects: 12
Study 31482309 — intervention group
Group type: COMPARATOR
Intervention: 3MAOT + placebo
Number of subjects: 12
Study 27488187 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Development Accounts (CDA) intervention, which included an Oklahoma 529 College Savings Plan account, financial incentives, and financial information.
Number of subjects: 2704
Study 27488187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDA intervention)
Number of subjects: 2704
Study 26251065 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused cognitive-behavioural therapy (CBT) and individual job support
Number of subjects: 1193
Study 26251065 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1193
Study 23290982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zoledronate 5 mg
Number of subjects: 2001
Study 23290982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2001
Study 21303636 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated SoloSTAR® pens (insulin glargine vs insulin glulisine)
Number of subjects: 400
Study 21303636 — intervention group
Group type: EXPERIMENTAL
Intervention: Undifferentiated SoloSTAR® pens
Number of subjects: 400
Study 21303636 — intervention group
Group type: COMPARATOR
Intervention: FlexPen® (insulin detemir vs insulin aspart)
Number of subjects: 400
Study 19577022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) 2 hours/day for 3 months
Number of subjects: 225
Study 19577022 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) treatment 2 hours/day for 3 months
Number of subjects: 225
Study 19577022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF)
Number of subjects: 225
Study 16455169 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation hepatitis B vaccine containing PreS1 and PreS2 antigens in addition to the S antigen
Number of subjects: 0
Study 16455169 — intervention group
Group type: COMPARATOR
Intervention: Conventional hepatitis B vaccine
Number of subjects: 0
Study 15523433 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal hemostatic sealant
Number of subjects: 70
Study 15523433 — intervention group
Group type: COMPARATOR
Intervention: Traditional suction cautery
Number of subjects: 70
Study 11704163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of metronidazole gel intravaginally
Number of subjects: 224
Study 11704163 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 224
Study 9561954 — intervention group
Group type: EXPERIMENTAL
Intervention: CSTAR program services
Number of subjects: 280
Study 7883389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 24
Study 7883389 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 24
Study 7883389 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 24
Study 3126085 — intervention group
Group type: EXPERIMENTAL
Intervention: Superselective intra-arterial chemotherapy with mitomycin C (SIAC)
Number of subjects: 47
Study 3126085 — intervention group
Group type: COMPARATOR
Intervention: Hepatic artery ligation (HAL) +/‐ 5-fluorouracil (5-FU)
Number of subjects: 47
Study 3126085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy toxicity after SIAC
Number of subjects: 47
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers often to always informed about the organisation of patient care
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers feeling their opinion is taken into account
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers reporting decision rights
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers reporting autonomy
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers reporting lack of information exchange
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers reporting ambiguity regarding tasks
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers expressing desire for stronger involvement in care organisation
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with professionals
Number of subjects: 2273
Study 31803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with nurses
Number of subjects: 2273
Study 29898670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (intervention group)
Number of subjects: 60
Study 29898670 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 25748415 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (two 500 mg tablets three times a day for 7 days)
Number of subjects: 2061
Study 25748415 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 2061
Study 24160442 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic CVD risk reduction package including healthy lifestyle counseling, prescription of a combination of drugs (antihypertensives, aspirin, and statin), and adherence support.
Number of subjects: 31708
Study 24160442 — intervention group
Group type: COMPARATOR
Intervention: Usual care for hypertension and diabetes management at individual clinicians' discretion.
Number of subjects: 31708
Study 24160442 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic CVD risk reduction package
Number of subjects: 31708
Study 22024856 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Number of subjects: 40
Study 22024856 — intervention group
Group type: COMPARATOR
Intervention: Saline/gentamicin irrigation
Number of subjects: 40
Study 18297400 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive services plus school-based mentoring (SBM)
Number of subjects: 516
Study 18297400 — intervention group
Group type: COMPARATOR
Intervention: Supportive services alone
Number of subjects: 516
Study 18297400 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive services plus SBM
Number of subjects: 516
Study 17133048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted suturing technique (IR)
Number of subjects: 103
Study 17133048 — intervention group
Group type: EXPERIMENTAL
Intervention: Single running sutures (SR)
Number of subjects: 103
Study 17133048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interrupted and running sutures (CIR)
Number of subjects: 103
Study 14519176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 411
Study 14519176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 11083312 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute geriatrics‐based ward (AGW)
Number of subjects: 413
Study 11083312 — intervention group
Group type: COMPARATOR
Intervention: General medical wards (MWs)
Number of subjects: 413
Study 11083312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AGW and MW
Number of subjects: 413
Study 8884548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2716
Study 1303480 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.04 mg/kg
Number of subjects: 2
Study 1303480 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone 1.05 mg/kg
Number of subjects: 2
Study 1303480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study 6099757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 355
Study 6099757 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (multiple doses)
Number of subjects: 355
Study 31205183 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical subtotal discectomy (MSD)
Number of subjects: 158
Study 29381803 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (12 mg)
Number of subjects: 20
Study 29381803 — intervention group
Group type: COMPARATOR
Intervention: Cold exposure (∼14.5°C for ≤2 hours)
Number of subjects: 20
Study 27055970 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids plus vitamin E
Number of subjects: 60
Study 27055970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23962492 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary School Action for Better Health (PSABH) programme to train teachers to deliver HIV-prevention education
Number of subjects: 26461
Study 19320914 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet group
Number of subjects: 287
Study 19320914 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape group
Number of subjects: 287
Study 19320914 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 287
Study 15777554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin (10, 20, 40, or 80 mg)
Number of subjects: 1089
Study 15777554 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy (10, 20, 40, or 80 mg)
Number of subjects: 1089
Study 11170979 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent antiretroviral therapy including ritonavir and saquinavir
Number of subjects: 41
Study 9929861 — intervention group
Group type: EXPERIMENTAL
Intervention: LactaPrev System (LPS)
Number of subjects: 55
Study 9929861 — intervention group
Group type: COMPARATOR
Intervention: Disposable breast pads
Number of subjects: 55
Study 7915294 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms/h for 48 hours following a bolus of 250 micrograms)
Number of subjects: 100
Study 7915294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no somatostatin)
Number of subjects: 100
Study 3202339 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthetic with 1.5 mg.kg‐1 prilocaine (RA)
Number of subjects: 35
Study 3202339 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic with 5 mg.kg‐1 thiopentone, dextromoramide, nitrous oxide and enflurane (GA)
Number of subjects: 35
Study 11898007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnut allergens identified through SDS-PAGE and IgE immunoblotting
Number of subjects: 72
Study 11898007 — intervention group
Group type: COMPARATOR
Intervention: Birch extract
Number of subjects: 72
Study 11898007 — intervention group
Group type: COMPARATOR
Intervention: Roasted hazelnut
Number of subjects: 72
Study 11898007 — intervention group
Group type: COMPARATOR
Intervention: Purified peach lipid-transfer protein (LTP)
Number of subjects: 72
Study 30175930 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg plus chlorthalidone
Number of subjects: 551
Study 30175930 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg plus chlorthalidone
Number of subjects: 551
Study 30175930 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone alone (Control)
Number of subjects: 551
Study 30175930 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil plus chlorthalidone
Number of subjects: 551
Study 30175930 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 551
Study 29933531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanhuangyilong decoction plus methotrexate (MTX)
Number of subjects: 0
Study 29933531 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) only
Number of subjects: 0
Study 24447649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 250
Study 24447649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 250
Study 24447649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 6 mg/day
Number of subjects: 250
Study 24447649 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 250
Study 24447649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 22551231 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 1383
Study 22551231 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone and combined behavioral intervention (CBI)
Number of subjects: 1383
Study 22551231 — intervention group
Group type: EXPERIMENTAL
Intervention: acamprosate and CBI
Number of subjects: 1383
Study 19968804 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised ambient temperature (26 degrees C)
Number of subjects: 60
Study 19968804 — intervention group
Group type: COMPARATOR
Intervention: Standard ambient temperature (21 degrees C)
Number of subjects: 60
Study 18534287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Talpha1)
Number of subjects: 73
Study 18534287 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 73
Study 15989416 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 72
Study 15989416 — intervention group
Group type: COMPARATOR
Intervention: Sit-up exercises
Number of subjects: 72
Study 15989416 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 72
Study 12798519 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe regimen (between 72 and 120 hours)
Number of subjects: 111
Study 12798519 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen (within 72 hours)
Number of subjects: 111
Study 10482480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin microemulsion preconcentrate (MEPC)
Number of subjects: 47
Study 8739805 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline monotherapy
Number of subjects: 25
Study 8739805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1750727 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg b.i.d.
Number of subjects: 15
Study 1750727 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg b.i.d.
Number of subjects: 15
Study 1750727 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 6751366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline 350 mg daily for 4 days followed by 700 mg daily for 4 days
Number of subjects: 21
Study 6751366 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets for 8 days
Number of subjects: 21
Study 30509740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks intravenously
Number of subjects: 495
Study 30509740 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (methotrexate, docetaxel, or cetuximab)
Number of subjects: 495
Study 30509740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 495
Study 30509740 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 495
Study 29282470 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (10 daily 30-minute, 2-mA sessions)
Number of subjects: 59
Study 29282470 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 59
Study 29282470 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 59
Study 26740484 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen therapy
Number of subjects: 441
Study 24488324 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib 400 mg with high-fat and high-calorie meal
Number of subjects: 22
Study 24488324 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (dose range 100-600 mg)
Number of subjects: 22
Study 22156624 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation docetaxel (D; Taxotere) after EP/XRT
Number of subjects: 243
Study 22156624 — intervention group
Group type: COMPARATOR
Intervention: Observation (O)
Number of subjects: 243
Study 22156624 — intervention group
Group type: EXPERIMENTAL
Intervention: EP/XRT (cisplatin and etoposide with concurrent chest radiation)
Number of subjects: 243
Study 22156624 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥ 70 years)
Number of subjects: 243
Study 20937567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine XR
Number of subjects: 153
Study 20937567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 16685703 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 16685703 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 16685703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15869669 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided VDD implantation
Number of subjects: 82
Study 15869669 — intervention group
Group type: COMPARATOR
Intervention: Left-sided VDD implantation
Number of subjects: 82
Study 11986603 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-heparin-bonded circuits with cardiotomy suction (group I)
Number of subjects: 36
Study 11986603 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits with cardiotomy suction (group II)
Number of subjects: 36
Study 11986603 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits without cardiotomy suction (group III)
Number of subjects: 36
Study 9706319 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-cognitive group intervention (ten, 2-hour weekly sessions)
Number of subjects: 50
Study 9706319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 9706319 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of drug/alcohol users and nonusers, fighters and nonfighters, and students threatened at school and those not threatened
Number of subjects: 50
Study 7618676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg by bolus injection followed by infusion (5 mg.h‐1 for 12 h and 2.5 mg.h‐1 for a further 12 h)
Number of subjects: 12
Study 7618676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg by bolus injection followed by infusion (10 mg.h‐1 for 12 h and 5 mg.h‐1 for a further 12 h)
Number of subjects: 12
Study 7618676 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulphate 2 mg by bolus injection followed by infusion (0.2 mg.h‐1 for 12 h and at 0.1 mg.h‐1 for further 12 h)
Number of subjects: 12
Study 2616934 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (specific treatment not mentioned)
Number of subjects: 0
Study 2616934 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (specific treatment not mentioned)
Number of subjects: 0
Study 339343 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2FPO3 containing toothpaste
Number of subjects: 0
Study 339343 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30319034 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatedly recalled the entire video (complete)
Number of subjects: 0
Study 30319034 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatedly recalled the traumatic (central) details of the event only (trauma‐focused)
Number of subjects: 0
Study 30319034 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatedly recalled the non‐traumatic (peripheral) details of the event only (non‐trauma focused)
Number of subjects: 0
Study 30319034 — intervention group
Group type: COMPARATOR
Intervention: No recall at all (no‐recall control)
Number of subjects: 0
Study 28750828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75/150 mg every 2 weeks)
Number of subjects: 720
Study 28750828 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 720
Study 28750828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 720
Study 28750828 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 720
Study 26712972 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg (Group O, n = 32)
Number of subjects: 66
Study 26712972 — intervention group
Group type: EXPERIMENTAL
Intervention: glycopyrrolate 0.2 mg (Group G, n = 31)
Number of subjects: 66
Study 24326013 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible spiral wire retainer
Number of subjects: 142
Study 24326013 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene woven ribbon retainer
Number of subjects: 142